- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01492192
RGD-PET-CT in Cancer Angiogenesis
Prospective Study of 18F-RGD PET-CT in Assessment of Response to Antiangiogenic Treatment in Patients With Cancer and Comparison With Perfusion CT
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 7LJ
- Department of Radiology, Oxford University Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients should have advanced or metastatic RCC confirmed by histological diagnosis
- Patients considered suitable for therapy with TKI for RCC according to responsible clinician
- Measurable tumour according to RECIST v1.1 criteria
- Standard staging CT scan performed within 28 days of first research scan
- The patient has not received chemotherapy, radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to recruitment
- Age ≥18 years
- Adequate renal function (creatinine <1.25xULN)
- Patient is able to tolerate and comply with scanning procedure
- Patient is not lactating or pregnant
- Absence of any psychological, familial, sociological or geographical condition which in the opinion of the Investigator may potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Able and willing to give informed consent
Exclusion Criteria:
- Not applicable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RCC Patients Antiangiogenic treatment
|
Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis. The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in tumour uptake of the fluciclatide imaging agent
Time Frame: Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
% change in SUVmax
|
Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumour response within an individual patient
Time Frame: Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
% change in size
|
Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
Changes of kinetic parameters on CT perfusion imaging
Time Frame: Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
BV, BF and Ki
|
Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
Absolute and relative tumour uptake and retention of fluciclatide
Time Frame: Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
|
|
Progression free survival at 12 months-
Time Frame: 12 months after the final reseach scan.
|
Time from last study scan to the date of disease progression or death due to the disease,whichever occurs first.
|
12 months after the final reseach scan.
|
Overall survival at 12 months
Time Frame: 12 months after the final reseach scan.
|
12 months after the final reseach scan.
|
|
Safety profile
Time Frame: within 12 months of the last research scan
|
Number of participants with adverse events attributed to the 18F-RDG-PET imaging agent (CTCAE Criteria)
|
within 12 months of the last research scan
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fergus Gleeson, Oxford University Hospitals NHS Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EP-TSC-663
- 2011-002833-20 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Renal Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...United States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
Clinical Trials on 18F-RGD-PET-CT and perfusion CT scans on 3 occasions
-
Radboud University Medical CenterRecruitingOropharyngeal Squamous Cell CarcinomaNetherlands
-
National Cancer Institute (NCI)CompletedNeurofibromatosis | MPNSTUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedBrain CancerUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnHistologically-confirmed MalignanciesUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingHead and Neck CancerUnited States
-
University Hospital Bispebjerg and FrederiksbergCompletedPatellofemoral Pain Syndrome | Anterior Knee Pain SyndromeDenmark
-
University of Lausanne HospitalsGeorge Coukos, MD PhD, Head of oncologyRecruiting
-
prof. dr. Koen Van LaereUniversitaire Ziekenhuizen KU Leuven; KU Leuven; University Hospital, Ghent; Fund...Not yet recruitingParkinson Disease | Alzheimer Disease | Dementia With Lewy Bodies | MSA - Multiple System AtrophyBelgium
-
British Columbia Cancer AgencyWithdrawnLiver Cirrhosis | Hepatocellular Carcinoma | Chronic Liver DiseaseCanada
-
London Health Sciences CentreCompleted